Výsledky vyhledávání - "Hayat Bähr-Mahmud"

Akademický článek

Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody

Autor: Hayat Bähr-Mahmud, Ursula Ellinghaus, Christiane R. Stadler, Leyla Fischer, Claudia Lindemann, Anuhar Chaturvedi, Jan Diekmann, Stefan Wöll, Imke Biermann, Bernhard Hebich, Caroline Scharf, Manuela Siefke, Alexandra S. Roth, Martin Rao, Kerstin Brettschneider, Eva-Maria Ewen, Uğur Şahin, Özlem Türeci

Publikováno v: OncoImmunology, Vol 12, Iss 1 (2023)

ABSTRACTIMAB362/Zolbetuximab, a first-in-class IgG1 antibody directed against the cancer-associated gastric-lineage marker CLDN18.2, has recently been reported to have met its primary endpoint in two phase 3 trials as a first-line treatment in combin

Externí odkaz: https://doaj.org/article/9d221a17a4384e5ba41b5f63a1b80c51

Zobrazit plný text záznamu

Akademický článek

EGFR-targeted granzyme B expressed in NK cells enhances natural cytotoxicity and mediates specific killing of tumor cells.

Autor: Pranav Oberoi, Robert A Jabulowsky, Hayat Bähr-Mahmud, Winfried S Wels

Publikováno v: PLoS ONE, Vol 8, Iss 4, p e61267 (2013)

Natural killer (NK) cells are highly specialized effectors of the innate immune system that hold promise for adoptive cancer immunotherapy. Their cell killing activity is primarily mediated by the pro-apoptotic serine protease granzyme B (GrB), which

Externí odkaz: https://doaj.org/article/ef704e3f72d1418d90548c650373682c

Zobrazit plný text záznamu

Erratum: Elimination of large tumors in mice by mRNA-encoded bispecific antibodies

Autor: Christiane R Stadler, Hayat Bähr-Mahmud, Leyla Celik, Bernhard Hebich, Alexandra S Roth, René P Roth, Katalin Karikó, Özlem Türeci, Ugur Sahin

Publikováno v: Nature medicine. 23(10)

This corrects the article DOI: 10.1038/nm.4356.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d98ccecc3db43198548322b2cd8d404
https://pubmed.ncbi.nlm.nih.gov/28604701

Zobrazit plný text záznamu

Elimination of large tumors in mice by mRNA-encoded bispecific antibodies

Autor: Alexandra S Roth, Katalin Karikó, Özlem Türeci, Bernhard Hebich, René P Roth, Ugur Sahin, Leyla Celik, Christiane Stadler, Hayat Bähr-Mahmud

Publikováno v: Nature medicine. 23(7)

The potential of bispecific T cell-engaging antibodies is hindered by manufacturing challenges and short serum half-life. We circumvented these limitations by treating mice with in vitro-transcribed pharmacologically optimized, nucleoside-modified mR

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64763dd92164b085ffe9c8f0f9f286df
https://pubmed.ncbi.nlm.nih.gov/28985209

Zobrazit plný text záznamu

EGFR-targeted granzyme B expressed in NK cells enhances natural cytotoxicity and mediates specific killing of tumor cells

Autor: Hayat Bähr-Mahmud, Robert A. Jabulowsky, Winfried S. Wels, Pranav Oberoi

Publikováno v: PLoS ONE
PLoS ONE, Vol 8, Iss 4, p e61267 (2013)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94f143994c02fa3cad9eb31b302d1193
http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/29641

Zobrazit plný text záznamu

Surface charge-modification prevents sequestration and enhances tumor-cell specificity of a recombinant granzyme B-TGFα fusion protein

Autor: Benjamin Dälken, Robert A. Jabulowsky, Winfried S. Wels, Hayat Bähr-Mahmud, Pranav Oberoi

Publikováno v: Bioconjugate chemistry. 23(8)

The serine protease granzyme B (GrB) plays an important role in the immune defense mediated by cytotoxic lymphocytes. Recombinant derivatives of this pro-apoptotic protein fused to tumor-targeting ligands hold promise for cancer therapy, but their ap

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2637d207f7e9bc6cb0ab7fd3a6a0a8c
https://pubmed.ncbi.nlm.nih.gov/22759275

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání